Sana Biotechnology Files 8-K
Ticker: SANA · Form: 8-K · Filed: 2025-01-13T00:00:00.000Z
Sentiment: neutral
Topics: disclosure, sec-filing
TL;DR
Sana Bio filed an 8-K, standard disclosure stuff.
AI Summary
On January 13, 2025, Sana Biotechnology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates Sana Biotechnology is making required disclosures to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Numbers
- 001-39941 — Commission File Number (Identifies the company's SEC filing record.)
- 83-1381173 — IRS Employer Identification Number (Tax identification number for the company.)
Key Players & Entities
- Sana Biotechnology, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- 188 East Blaine Street, Suite 400 (location) — Principal executive offices address
- Seattle, Washington 98102 (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for Regulation FD disclosures and to report financial statements and exhibits.
What is the exact date of the earliest event reported?
The date of the earliest event reported is January 13, 2025.
Where are Sana Biotechnology, Inc.'s principal executive offices located?
The principal executive offices are located at 188 East Blaine Street, Suite 400, Seattle, Washington 98102.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SIC code for Sana Biotechnology, Inc.?
The Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 657 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-13 09:00:51
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SANA The Nasdaq
Filing Documents
- d880140d8k.htm (8-K) — 26KB
- d880140dex991.htm (EX-99.1) — 36KB
- g880140ex99_1p10g1.jpg (GRAPHIC) — 234KB
- g880140ex99_1p11g1.jpg (GRAPHIC) — 318KB
- g880140ex99_1p12g1.jpg (GRAPHIC) — 265KB
- g880140ex99_1p13g1.jpg (GRAPHIC) — 261KB
- g880140ex99_1p14g1.jpg (GRAPHIC) — 307KB
- g880140ex99_1p15g1.jpg (GRAPHIC) — 291KB
- g880140ex99_1p16g1.jpg (GRAPHIC) — 581KB
- g880140ex99_1p17g1.jpg (GRAPHIC) — 559KB
- g880140ex99_1p18g1.jpg (GRAPHIC) — 252KB
- g880140ex99_1p19g1.jpg (GRAPHIC) — 268KB
- g880140ex99_1p1g1.jpg (GRAPHIC) — 81KB
- g880140ex99_1p20g1.jpg (GRAPHIC) — 355KB
- g880140ex99_1p21g1.jpg (GRAPHIC) — 349KB
- g880140ex99_1p22g1.jpg (GRAPHIC) — 327KB
- g880140ex99_1p23g1.jpg (GRAPHIC) — 274KB
- g880140ex99_1p24g1.jpg (GRAPHIC) — 261KB
- g880140ex99_1p25g1.jpg (GRAPHIC) — 286KB
- g880140ex99_1p26g1.jpg (GRAPHIC) — 324KB
- g880140ex99_1p27g1.jpg (GRAPHIC) — 204KB
- g880140ex99_1p28g1.jpg (GRAPHIC) — 321KB
- g880140ex99_1p29g1.jpg (GRAPHIC) — 295KB
- g880140ex99_1p2g1.jpg (GRAPHIC) — 532KB
- g880140ex99_1p30g1.jpg (GRAPHIC) — 300KB
- g880140ex99_1p31g1.jpg (GRAPHIC) — 365KB
- g880140ex99_1p32g1.jpg (GRAPHIC) — 268KB
- g880140ex99_1p33g1.jpg (GRAPHIC) — 353KB
- g880140ex99_1p34g1.jpg (GRAPHIC) — 277KB
- g880140ex99_1p35g1.jpg (GRAPHIC) — 64KB
- g880140ex99_1p3g1.jpg (GRAPHIC) — 328KB
- g880140ex99_1p4g1.jpg (GRAPHIC) — 367KB
- g880140ex99_1p5g1.jpg (GRAPHIC) — 374KB
- g880140ex99_1p6g1.jpg (GRAPHIC) — 257KB
- g880140ex99_1p7g1.jpg (GRAPHIC) — 261KB
- g880140ex99_1p8g1.jpg (GRAPHIC) — 223KB
- g880140ex99_1p9g1.jpg (GRAPHIC) — 219KB
- 0001193125-25-005047.txt ( ) — 14805KB
- sana-20250113.xsd (EX-101.SCH) — 3KB
- sana-20250113_lab.xml (EX-101.LAB) — 18KB
- sana-20250113_pre.xml (EX-101.PRE) — 11KB
- d880140d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits See the Exhibit Index below, which is incorporated by reference herein. EXHIBIT INDEX Exhibit Number Description 99.1 Corporate Presentation dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sana Biotechnology, Inc. Date: January 13, 2025 By: /s/ Bernard J. Cassidy Bernard J. Cassidy Executive Vice President and General Counsel